Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial

K. Hideghéty, Wolfgang Sauerwein, Andrea Wittig, Claudia Götz, Philippe Paquis, Frank Grochulla, Klaus Haselsberger, John Wolbers, Ray Moss, Rene Huiskamp, Heinz Frankhauser, Martin De Vries, Detlef Gabel

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: The uptake of the boron compound Na2B12H10-SH (BSH) in tumor and normal tissues was investigated in the frame of the EORTC phase I trial 'Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility' (protocol 11961). Methods and materials: The boron concentration in blood, tumor, normal brain, dura, muscle, skin and bone was detected using inductively coupled plasma-atomic emission spectroscopy in 13 evaluable patients. In a first group of 10 patients 100 mg BSH/kg bodyweight (BW) were administered; a second group of 3 patients received 22.9 mg BSH/kg BW. The toxicity due to BSH was evaluated. Results: The average boron concentration in the tumor was 19.9 ± 9.1 ppm (1 standard deviation (SD)) in the high dose group and 9.8 ± 3.3 ppm in the low dose group, the tumor/blood ratios were 0.6 ± 0.2 and 0.9 ± 0.2, respectively. The highest boron uptake has been detected in the dura, very low uptake was found in the bone, the cerebro-spinal fluid and especially in the brain (brain/blood ratio 0.2 ± 0.02 and 0.4 ± 0.2). No toxicity was detected except flush-like symptoms in 2 cases during a BSH infusion at a much higher speed than prescribed. Conclusion: BSH proved to be safe for clinical application at a dose of 100 mg BSH/kg infused and at a dose rate of 1 mg/kg/min. The study underlines the importance of a further investigation of BSH uptake in order to obtain enough data for significant statistical analysis. The boron concentration in blood seems to be a quite reliable parameter to predict the boron concentration in other tissues.

Original languageEnglish
Pages (from-to)145-156
Number of pages12
JournalJournal of Neuro-Oncology
Volume62
Issue number1-2
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Boron
Glioblastoma
Boron Compounds
Bone and Bones
Atomic Spectrophotometry
Neoplasms
Statistical Data Interpretation
Brain
Blood Group Antigens
Brain Neoplasms
Cerebrospinal Fluid
Muscles
Skin

Keywords

  • BNCT
  • BSH tissue uptake
  • BSH toxicity
  • Glioblastoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Hideghéty, K., Sauerwein, W., Wittig, A., Götz, C., Paquis, P., Grochulla, F., ... Gabel, D. (2003). Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. Journal of Neuro-Oncology, 62(1-2), 145-156. https://doi.org/10.1023/A:1023201308434

Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. / Hideghéty, K.; Sauerwein, Wolfgang; Wittig, Andrea; Götz, Claudia; Paquis, Philippe; Grochulla, Frank; Haselsberger, Klaus; Wolbers, John; Moss, Ray; Huiskamp, Rene; Frankhauser, Heinz; De Vries, Martin; Gabel, Detlef.

In: Journal of Neuro-Oncology, Vol. 62, No. 1-2, 03.2003, p. 145-156.

Research output: Contribution to journalArticle

Hideghéty, K, Sauerwein, W, Wittig, A, Götz, C, Paquis, P, Grochulla, F, Haselsberger, K, Wolbers, J, Moss, R, Huiskamp, R, Frankhauser, H, De Vries, M & Gabel, D 2003, 'Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial', Journal of Neuro-Oncology, vol. 62, no. 1-2, pp. 145-156. https://doi.org/10.1023/A:1023201308434
Hideghéty, K. ; Sauerwein, Wolfgang ; Wittig, Andrea ; Götz, Claudia ; Paquis, Philippe ; Grochulla, Frank ; Haselsberger, Klaus ; Wolbers, John ; Moss, Ray ; Huiskamp, Rene ; Frankhauser, Heinz ; De Vries, Martin ; Gabel, Detlef. / Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. In: Journal of Neuro-Oncology. 2003 ; Vol. 62, No. 1-2. pp. 145-156.
@article{5a0dc1ef63914c23ba63cf1ee32997a0,
title = "Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial",
abstract = "Purpose: The uptake of the boron compound Na2B12H10-SH (BSH) in tumor and normal tissues was investigated in the frame of the EORTC phase I trial 'Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility' (protocol 11961). Methods and materials: The boron concentration in blood, tumor, normal brain, dura, muscle, skin and bone was detected using inductively coupled plasma-atomic emission spectroscopy in 13 evaluable patients. In a first group of 10 patients 100 mg BSH/kg bodyweight (BW) were administered; a second group of 3 patients received 22.9 mg BSH/kg BW. The toxicity due to BSH was evaluated. Results: The average boron concentration in the tumor was 19.9 ± 9.1 ppm (1 standard deviation (SD)) in the high dose group and 9.8 ± 3.3 ppm in the low dose group, the tumor/blood ratios were 0.6 ± 0.2 and 0.9 ± 0.2, respectively. The highest boron uptake has been detected in the dura, very low uptake was found in the bone, the cerebro-spinal fluid and especially in the brain (brain/blood ratio 0.2 ± 0.02 and 0.4 ± 0.2). No toxicity was detected except flush-like symptoms in 2 cases during a BSH infusion at a much higher speed than prescribed. Conclusion: BSH proved to be safe for clinical application at a dose of 100 mg BSH/kg infused and at a dose rate of 1 mg/kg/min. The study underlines the importance of a further investigation of BSH uptake in order to obtain enough data for significant statistical analysis. The boron concentration in blood seems to be a quite reliable parameter to predict the boron concentration in other tissues.",
keywords = "BNCT, BSH tissue uptake, BSH toxicity, Glioblastoma",
author = "K. Hidegh{\'e}ty and Wolfgang Sauerwein and Andrea Wittig and Claudia G{\"o}tz and Philippe Paquis and Frank Grochulla and Klaus Haselsberger and John Wolbers and Ray Moss and Rene Huiskamp and Heinz Frankhauser and {De Vries}, Martin and Detlef Gabel",
year = "2003",
month = "3",
doi = "10.1023/A:1023201308434",
language = "English",
volume = "62",
pages = "145--156",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial

AU - Hideghéty, K.

AU - Sauerwein, Wolfgang

AU - Wittig, Andrea

AU - Götz, Claudia

AU - Paquis, Philippe

AU - Grochulla, Frank

AU - Haselsberger, Klaus

AU - Wolbers, John

AU - Moss, Ray

AU - Huiskamp, Rene

AU - Frankhauser, Heinz

AU - De Vries, Martin

AU - Gabel, Detlef

PY - 2003/3

Y1 - 2003/3

N2 - Purpose: The uptake of the boron compound Na2B12H10-SH (BSH) in tumor and normal tissues was investigated in the frame of the EORTC phase I trial 'Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility' (protocol 11961). Methods and materials: The boron concentration in blood, tumor, normal brain, dura, muscle, skin and bone was detected using inductively coupled plasma-atomic emission spectroscopy in 13 evaluable patients. In a first group of 10 patients 100 mg BSH/kg bodyweight (BW) were administered; a second group of 3 patients received 22.9 mg BSH/kg BW. The toxicity due to BSH was evaluated. Results: The average boron concentration in the tumor was 19.9 ± 9.1 ppm (1 standard deviation (SD)) in the high dose group and 9.8 ± 3.3 ppm in the low dose group, the tumor/blood ratios were 0.6 ± 0.2 and 0.9 ± 0.2, respectively. The highest boron uptake has been detected in the dura, very low uptake was found in the bone, the cerebro-spinal fluid and especially in the brain (brain/blood ratio 0.2 ± 0.02 and 0.4 ± 0.2). No toxicity was detected except flush-like symptoms in 2 cases during a BSH infusion at a much higher speed than prescribed. Conclusion: BSH proved to be safe for clinical application at a dose of 100 mg BSH/kg infused and at a dose rate of 1 mg/kg/min. The study underlines the importance of a further investigation of BSH uptake in order to obtain enough data for significant statistical analysis. The boron concentration in blood seems to be a quite reliable parameter to predict the boron concentration in other tissues.

AB - Purpose: The uptake of the boron compound Na2B12H10-SH (BSH) in tumor and normal tissues was investigated in the frame of the EORTC phase I trial 'Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation Facility' (protocol 11961). Methods and materials: The boron concentration in blood, tumor, normal brain, dura, muscle, skin and bone was detected using inductively coupled plasma-atomic emission spectroscopy in 13 evaluable patients. In a first group of 10 patients 100 mg BSH/kg bodyweight (BW) were administered; a second group of 3 patients received 22.9 mg BSH/kg BW. The toxicity due to BSH was evaluated. Results: The average boron concentration in the tumor was 19.9 ± 9.1 ppm (1 standard deviation (SD)) in the high dose group and 9.8 ± 3.3 ppm in the low dose group, the tumor/blood ratios were 0.6 ± 0.2 and 0.9 ± 0.2, respectively. The highest boron uptake has been detected in the dura, very low uptake was found in the bone, the cerebro-spinal fluid and especially in the brain (brain/blood ratio 0.2 ± 0.02 and 0.4 ± 0.2). No toxicity was detected except flush-like symptoms in 2 cases during a BSH infusion at a much higher speed than prescribed. Conclusion: BSH proved to be safe for clinical application at a dose of 100 mg BSH/kg infused and at a dose rate of 1 mg/kg/min. The study underlines the importance of a further investigation of BSH uptake in order to obtain enough data for significant statistical analysis. The boron concentration in blood seems to be a quite reliable parameter to predict the boron concentration in other tissues.

KW - BNCT

KW - BSH tissue uptake

KW - BSH toxicity

KW - Glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=0038369125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038369125&partnerID=8YFLogxK

U2 - 10.1023/A:1023201308434

DO - 10.1023/A:1023201308434

M3 - Article

C2 - 12749710

AN - SCOPUS:0038369125

VL - 62

SP - 145

EP - 156

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -